Our portfolio of proprietary enabling technologies combined with our team of industry experts and scalable partnering approach, allows us to support all your needs from discovery through commercialization. We offer endto-end, full-service solutions that include upfront discovery, assay development, clinical testing, regulatory filing, cGMP manufacturing and global product commercialization.
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume, we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
For more information visit www.olink.com
Randox Biosciences are a highly innovative global leader in clinical diagnostic manufacturing supplying the world’s top CRO’s and biopharmaceutical companies. We have technical expertise in diagnostic and CDx assay development utilising single analyte assays, as well as multiplex assays that test up to 23 biomarkers using one patient sample via our Evidence range of analysers. This utilises our proprietary Biochip Array Technology which was developed using our in house range of antibodies, proteins and conjugates. We also offer a custom development service for all our raw materials for the biopharmaceutical and diagnostic industries. As well as custom assay development, our custom services also include polyclonal and monoclonal development and recombinant antibody fragments (sdAb, scFv, Fab).
Genomenon provides immediate insight into the published genomic research for every disease, gene, and mutation found in the scientific literature.
Pharmaceutical and biotech companies license Genomenon’s comprehensive genomic landscape on any given disease to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets